சியோல் தேசிய பல்கலைக்கழகம் விலங்கு மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சியோல் தேசிய பல்கலைக்கழகம் விலங்கு மருத்துவமனை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சியோல் தேசிய பல்கலைக்கழகம் விலங்கு மருத்துவமனை Today - Breaking & Trending Today

GNT Pharmas GedaCure Approved for the Treatment of Dogs With Cognitive Dysfunction Syndrome


Posted on
323
GNT Pharma today announced the Korea Animal and Plant Quarantine Agency (APQA) has approved the New Drug Application for GedaCure®, a chewable tablet of crisdesalazine, for the treatment of dogs with cognitive dysfunction syndrome (CDS) that suffer from disorientation, altered interactions with family, sleep-wake cycle disturbance, house soiling and changes in activity with aging.
GedaCure® is the world’s first multi-target neuroprotection drug for canine cognitive dysfunction syndrome. It is expected to improve the quality of life of aged dogs with CDS and their owners. GNT Pharma plans to launch GedaCure® in South Korea and will push ahead in earnest to advance globally for dogs and their family who suffer from CDS. ....

Soult Ukpyolsi , South Korea , Jinhwan Lee , Plant Quarantine Agency , Seoul National University Animal Hospital , Animal Healthcare , Korea Animal , New Drug Application , Seoul National University Animal , தெற்கு கொரியா , சியோல் தேசிய பல்கலைக்கழகம் விலங்கு மருத்துவமனை , விலங்கு சுகாதாரம் , கொரியா விலங்கு , புதியது மருந்து விண்ணப்பம் , சியோல் தேசிய பல்கலைக்கழகம் விலங்கு ,

GNT Pharma's GedaCure® Approved for the Treatment of Dogs With Cognitive Dysfunction Syndrome


GNT Pharma s GedaCure® Approved for the Treatment of Dogs With Cognitive Dysfunction Syndrome
Wednesday, February 10, 2021 4:52PM IST (11:22AM GMT)
New drug showing symptomatic relief and disease-modifying potential in canine cognitive dysfunction syndrome 
 
Yongin, South Korea:
 
GNT Pharma today announced the Korea Animal and Plant Quarantine Agency (APQA) has approved the New Drug Application for GedaCure®, a chewable tablet of crisdesalazine, for the treatment of dogs with cognitive dysfunction syndrome (CDS) that suffer from disorientation, altered interactions with family, sleep-wake cycle disturbance, house soiling and changes in activity with aging.
 
GedaCure® is the world’s first multi-target neuroprotection drug for canine cognitive dysfunction syndrome. It is expected to improve the quality of life of aged dogs with CDS and their owners. GNT Pharma plans to launch G ....

Soult Ukpyolsi , South Korea , Jinhwan Lee , Plant Quarantine Agency , Seoul National University Animal Hospital , Animal Healthcare , Korea Animal , New Drug Application , Seoul National University Animal , Media Contact , Health Care , Gnt Pharma , Treatment Of Dogs , Cognitive Dysfunction Syndrome , Canine Cognitive Dysfunction , Animal And Plant Quarantine Agency , Alzheimers Disease , Canine Cds , Neurodegenerative Disease , Hwa Young Youn , Byoung Joo Gwag , தெற்கு கொரியா , சியோல் தேசிய பல்கலைக்கழகம் விலங்கு மருத்துவமனை , விலங்கு சுகாதாரம் , கொரியா விலங்கு , புதியது மருந்து விண்ணப்பம் ,